Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-11-06
2007-11-06
Lewis, Patrick (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
10278703
ABSTRACT:
The invention relates to the therapeutic or prophylactic treatment of fungal infections. The invention provides new methods for therapeutically or prophylactically treating fungal infections using sub-lethal concentrations of an anti-invasin compound. The methods according to the invention have fewer toxicology problems than existing methods, and thus can be used prophylactically, as well as for early treatment for high risk patients without a firm diagnosis. The methods according to the invention can also be used to treat an established fungal infection. The invention further provides novel genes that regulate fungal hyphal growth.
REFERENCES:
patent: 5833946 (1998-11-01), Tamburini et al.
Mandels et al. J. Bacteriol. 1953 January; 65(1): 16-26.
Alex, Lisa A. et al.; COS1, a two-component histidine kinase that is involved in hyphal development in the opportunistic pathogenCandida albicans; Proc. Natl. Acad. Sci. USA 95: 7069-7073 (1998).
Alonso-Monge, R. et al.; Role of the Mitogen-Activated Protein Kinase Hog1p in Morphogenesis and Virulence ofCandida albicans; J. Bacteriology, 181: 3058-3068 (1999).
Baillie, George A., et al.; Candida Biofilms and Their Susceptibility to Antifungal Agents; Methods in Enzymology 310: 644-656 (1999).
Braga, P.C., et al.; Effects of Subinhibitory Concentrations of Ciclopirox on the Adherence ofCandida albicansto Human Buccal and Vaginal Epithelial Cells;Antimycotics-Fungicides 42: 1368-1371 (1992).
Braga, P.C., et al.; Experimental Evidences for a Role of Subinhibitory Concentrations of Rilopirox, Nystatin and Fluconazole on Adherence of Candida spp. to Vaginal Epithelial Cells; Chemotherapy 42: 259-265 (1996).
Bremm, K. D., et al.; Influence of Azole Componds on Adhesion, Germ Tube Formation and Virulance ofC. albicansin Cell Cultures and Infected Animals; Candida and Candidamycosis (E. Tumbay, Ed.), 97-100; Plenum Press, New York (1991).
Brenciaglia, M. I., et al.; The Influence of Antifungal Drugs on Adherence ofCandida albicansto Buccal Epithelial Cells; Chemioterapia 5: 200-203 (1986).
Calera, Jose Antonio, et al.; Defective Hyphal Development and Avirulence Caused by a Deletion of the SSK1 Response Regulator Gene inCandida albicans; infection and Immunity 68: 518-525 (2000.
Csank, Csilla, et al.; Roles of theCandida albicansMitogen-Activated Protein Kinase Homolog, Cek1p, in Hhphal Development and Systemic Candidiasis; Injection and Immunity 66: 2713-2721
Ellepola, A. N. B., et al.; Adhesion of oralC. albicansto human buccal epithelial cells following limted exposure to antifungal agents; J. Oral Pathol. Med. 27: 325-332 (1998).
Ellepola, A. N. B. , et al.; Adhesion of oralCandida albicansisolates to denture acrylic following limted exposure to antifungal agents; Arch. Oral. Biol. 43:999-1007 (1998.
Ellepola, A. N. B., et al; The effect of limited exposure to antifungal agents on the germ tube formation of oralCandida albican; J. Oral Pathol. Med. 27: 213-219 (1998).
Ghannoum, Mahmound A., et a;.; Modulation of Interactions ofCandida albicansand Endothelia Cells by Fluconazole and Amphotericin B; Antimicrobia Agents Chemotherapy; 36:2239-2244. (1992).
Ha, Kien C., et al.; Effects of Azole Antifungal Drugs on the Transition from Yeast Cells to Hyphae in Susceptible and Resistant Isolates of the Pathogenic YeastCandida albicans; Antimicrobial Agents and Chemotherapy 43: 763-768 (1999).
Haller, Ingo: Mode of action of clotrimazole: Implications for therapy; Am. J. Obstet, Gynecol. 152: 939-944 (1985).
Hawser, Stepen, et al.; The effects of antigual agents on the morphogentic transformation byCandia albicansin vitro; J. Antimicrob. Chemother. 38: 579-587 (1996).
Hawser, Stephen, et al.; Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation ofCandida albicans; J. Antimicrob. Chemother. 43: 411-413 (1999).
Kretschmar, Marianne, et al.; Germ Tubes and Proteinase Activity Contribute to Virulence ofCandida albicansin Murine Peritonitis; Infection and Immunity 67: 6637-6642 (1999).
Lo, Hsiu-Jung, et al.; NonfilamentousC. albicansMutants Are Avirulent; Cell 90: 939-949 (1997).
Martin, Michael V.; The use of fluconazole and itraconazole in the treatment ofCandida albicansinfections: a review; J. Antimicrob. Chemother. 44: 429-437 (1999).
Mehentee, J.F., et al.; Effect of antifungal agents on the adherence ofCandida albicansto murine gastrointestinal mucosal surfaces; J. Antimicrob. Chemother. 25: 111-119 (19900.
Nugent, Kenneth M., et al.; Effects of Sublethal Concentrations of Amphotericin B onCandida albicans; J. Infect. Dis. 154: 665-669 (1986).
Norman, Thea C., et al.; Genetic Selection of Peptide Inhibitors of Biological Pahthways; 285: 591-595 (1999).
Philpott-Howard, J. N.; et al.; Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia: J. Antimicrob. Chemother. 31: 973-984 (1993).
Plempel, M., et al.; Reduction of the In Vivo Virulence ofCandida albicansby Pretreatment with Subinhibitory Azole Concentrations In Vitro; Dermatologica 169: Suppl. 1.11-18 (1984).
Staab, Janet F., et al.; Developmental Expression of a Tandemly Repeated, Proline-and Glutamine-rich Amino Acid Motif on Hyphal Surfaces ofCandida albicans; J. Biological Chemistry 271: 6298-6306 (1996).
Van't Wout, Jan W., et al.; Effect of amphotericin B, fluconazole and intraconazole on intracellularCandida albicansand germ tube development in macrophages; J. Antimicrob, Chemother. 25: 803-811 (1990).
Weig, Michael, et al.; Clinical aspects and pathogenesis of Candida infection; Trends in Microbiology 6: 468-470 (1998).
Braga et al., “Inhibition ofCandida albicansAdhesiveness to Human Buccal and Vaginal Cells . . . ” Arzneimittel Forschung. Drug Research, Editio Cantor. Aulendorf, DE, vol. 45:84-87, 1995.
Haller, I., “Zum Wirkengstyp von Imidazol-Antimykotika: Konsequenzen fur die . . . ” Mykosen 22:423-430, 1979.
Macura, A/. “The Influence of Some Antifungal Drugs on In Vitro Adherence ofCandida albicansto Human . . . ” Mycoses 31:371-376, 1988.
Nosanchuk et al., “Amphotericin B and Fluconazole Affect Cellular Charge, Macrophage Phagocytosis, . . . ” Antimicrobial Agents and Chem. 43:233-239, 1999.
Osumi et al., “The Effect of Bifonazole on the Structure of Trichophyton” Arzneimittel-Forschung, Germany 33:1484-1491, 1983.
Schaude et al., “Inhibitory Effect of Antifungal Agents on Germ Tube Formation inCandida albicans” Mykosen 30:281-287, 1987.
Teen et al., “Effects of Sub-Inhibitory Concentrations of Antifungal Agents on Adherence of . . . ” Mycoses 32:551-562, 1989.
Wills et al., “New Potential Targets for Antifungal Development” Emerging Therapeutic Targets 4:1-32, 2000.
Cali Brian
Cordero Etchell
Hecht Peter
Milne Todd
Salama Sofie
Fish & Richardson P.C.
Lewis Patrick
Microbia, Inc.
LandOfFree
Use of sublethal concentrations of anti-invasin compounds to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of sublethal concentrations of anti-invasin compounds to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of sublethal concentrations of anti-invasin compounds to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3854729